Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells

Clinical Cancer Research

Volumn 7, Issue 8, 2001, Pages 2237-2245

  Weeraratna, Ashani T ^a   Dalrymple, Susan L ^a   Lamb, John C ^a   Denmeade, Samuel R ^a   Isaacs, John T ^a,b   Miknyoczki, Sheila ^c   Dionne, Craig A ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEP 701; NEUROTROPHIN; PROTEIN TYROSINE KINASE; TYROSINE KINASE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG TUMOR LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBAZOLES; CELL DIVISION; CELL LINE; DISEASE MODELS, ANIMAL; HUMANS; INDOLES; MALE; MICE; MICE, NUDE; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RATS; RECEPTOR, TRKA; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034881357     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Programmed cell death during regression of the PC-82 human prostate cancer following androgen ablation
2. Development of an androgen receptornull model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells
3. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma
4. Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system
5. Androgen-independent prostate cancer progression in the TRAMP model
6. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process
7. Heparin binding affinity of rat prostatic growth factor in normal and cancerous prostates: Partial purification and characterization of rat prostatic growth factor in the Dunning tumor
8. Production of IGF-II-related peptide by an anaplastic cell line (AT-3) established from the Dunning prostatic carcinoma of rats
9. Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues
10. Rational basis for trk inhibition therapy for prostate cancer
11. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
12. Implication of the cell kinetic changes during the progression of human prostatic cancer
13. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587)
14. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555)
15. Intracellular signaling pathways activated by neurotrophic factors
16. Tyrosine kinase receptor-activated signal transduction pathway which lead to oncogenesis
17. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal
18. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
19. Regulation of cell death protease caspase-9 by phosphorylation
20. CEP-751 inhibits trk receptor tyrosine kinase activity in vitro and exhibits anti-tumor activity
21. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers
22. Location of KAII on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer
23. A new human prostate carcinoma cell line, 22Rv1
24. Ki-67 immunoexpression is a robust marker of proliferative cells in the rat
25. TUNEL apoptotic cell detection in tissue sections: Critical evaluation and improvement
26. Relationship between tumor size and the curability of metastatic prostatic cancer by surgery alone or in combination with adjuvant chemotherapy
27. Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: Critical threshold concept
28. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen
29. Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas
30. Nerve growth factor stimulates in vitro invasive capacity of DU145 human prostatic cancer cells
31. The trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma